Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Drug development train gathering steam

Nature Medicine volume 2, pages 403–404 (1996)Cite this article

Inhibitors of specific signaling molecules may provide future treatments for acute lymphocytic leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cortes, J.E. & Kantarjian, H.M. Acute lymphoblastic leukemia — a comprehensive review with emphasis on biology and therapy. Cancer 76, 2393–2417 (1995).

    Article  CAS  Google Scholar 

  2. Ihle, J.N. Cytokine receptor signaling. Nature 377, 591–594 (1995).

    Article  CAS  Google Scholar 

  3. Levitski, A. & Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 267, 1782–1789 (1995).

    Article  Google Scholar 

  4. Meydan, N. et al. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 379, 645–648 (1996).

    Article  CAS  Google Scholar 

  5. Dvir, A. et al. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J. Cell Biol. 113, 857–865 (1991).

    Article  CAS  Google Scholar 

  6. Kaur, G. et al. Tyrphostin induced growth inhibition: Correlation with effect on p210 bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 5, 213–222 (1994).

    Article  CAS  Google Scholar 

  7. Migone, T.S. et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79–81 (1995).

    Article  CAS  Google Scholar 

  8. Danial, N.N., Pernis, A. & Rothman, P.B. Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875–1877 (1995).

    Article  CAS  Google Scholar 

  9. Karp, J.E. & Broder, S. New directions in molecular medicine. Cancer Res. 54, 653–665 (1994).

    CAS  PubMed  Google Scholar 

  10. Gibbs, J.B., Oliff, A. & Kohl, N.E. Farnesyl-transferase inhibitors. Ras research yields a potential cancer therapeutic. Cell 77, 175–178 (1994).

    Article  CAS  Google Scholar 

  11. James, G.L. et al. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937–1942 (1993).

    Article  CAS  Google Scholar 

  12. Jones, R.J. et al. Bryostatin 1, a unique biologic response modifier: Anti-leukemic activity in vitro. Blood 75, 1319–1323 (1990).

    CAS  PubMed  Google Scholar 

  13. May, W.S. et al. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 84, 8483–8487 (1987).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sealy Center for Oncology and Hematology, The University of Texas Medical Branch at Galveston, Galveston, Texas, 77555-1048, USA

    Takahiko Ito & W. Stratford May

Authors
  1. Takahiko Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Stratford May
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ito, T., May, W. Drug development train gathering steam. Nat Med 2, 403–404 (1996). https://doi.org/10.1038/nm0496-403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0496-403

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing